1,599 research outputs found

    Sociodrama “alcalosis respiratoria”, en bioquímica, en el CICS UMAIPN

    Get PDF
    El CICS UMA al ser dependiente del Instituto Politécnico Nacional, tiene como guía de trabajo académico cotidiano las estrategias educativas que emanan de los elementos del Modelo Educativo Institucional (MEI). Por otro lado, el ejercicio docente obliga a la formación y desarrollo continuo del docente, estableciendo como prioridades la mejora continua de su práctica docente y de investigación. Producto de lo anterior fue la implementación de una estrategia de aprendizaje, como es, el Sociodrama “Un caso de Alcalosis Respiratoria” en la Unidad de Aprendizaje, Fundamentos de Nutrición Clínica I Bioquímica en el aparato respiratorio, en la Carrera de Nutrición del CICS UMA. Que nos llevó a la representación de un contenido temático del programa, obteniendo como resultado, los alumnos se muestran muy participativos, es dinámica, versátil y útil para la conclusión y retroalimentación de los contenidos de una Unidad de Aprendizaje y que puede ser usado con grupos numerosos.The CICS UMA, being dependent on the National Polytechnic Institute, has as a guide of daily academic work the educational strategies that emanate from the elements of the Institutional Educational Model (MEI). On the other hand, the teaching exercise requires the continuous training and development of the teacher, establishing as priorities the continuous improvement of their teaching and research practice. Product of the above was the implementation of a learning strategy, such as, the Sociodrama "A Case of respiratory alkalosis" in the Learning Unit, Fundamentals of Clinical Nutrition I Biochemistry in the respiratory system, in the Nutrition Career of CICS UMA. That led us to the representation of a thematic content of the program, obtaining as a result, the students are very participative, dynamic, versatile and useful for the conclusion and feedback of the contents of a Learning Unit and that can be used with groups numerous

    Aplicación del sistema de aprendizaje basado en la investigación (SABI) en la unidad de bioquímica del CICS UMA-IPN

    Get PDF
    El aprendizaje es un proceso corresponsable, participativo y permanente, donde intervienen: el aprendiz, docente, condiscípulos, institución y demás factores sociales donde se desenvuelve el estudiante. Como elemento detonador del aprendizaje está la investigación, que se realiza a partir de hechos reales que son abordados sobre la base del desarrollo científico del estado del arte. Uno de los elementos fundamentales en la formación profesional de los alumnos es el método que se utilice. El Sistema de Aprendizaje Basado en la Investigación es una innovación educativa (SABI), el cual se utilizó en la unidad de aprendizaje de Ciencias Básicas del Aparato Cardiovascular en las generaciones 33ª, 34ª, 35ª, 36ª y 37ª en los años del 2008 al 2012 de la Carrera de Medicina y como resultado se obtuvo una disminución en el número de alumnos reprobados, mejorándose el aprovechamiento. Este método es una excelente alternativa en el proceso enseñanza-aprendizaje y se puede emplear en grupos con un número variable de alumnos.Learning is a steward, permanent, and participatory process where: the apprentice, teacher, classmates, institution and other social factors where the student performs. As detonator of learning is research, which is made from real events that are addressed on the basis of the scientific development of the state of art. One of the key elements in the professional training of students is the method that is used. Research-based learning system is an educational innovation (SABI), which was used in the learning of basic sciences of the Cardiovascular Apparatus in generations’ unit 33rd, 34th, 35th, 36th and 37th in the years of 2008 to 2012's career in medicine and as a result was a decrease in the number of student’s reproached improving achievement. This method is an excellent alternative in the teachinglearning process and can be used in groups with a variable number of students

    Una experiencia del uso de los ambientes virtuales en bioquímica, en la especialidad en función visual del CICS UMA-IPN

    Get PDF
    El Instituto Politécnico Nacional se encuentra en un período de modificación, que ha implicado la creación de nuevas propuestas pedagógicas orientadas a la promoción del aprendizaje destacando la educación virtual, que en los últimos años ha favorecido la aparición y consolidación de Licenciaturas, Diplomados, Especialidades, Maestrías entre otras, empleando la formación a distancia basadas en un entorno web. Este trabajo recopila la experiencia que se ha tenido en el curso Bioquímica impartido en la Especialidad de Función Visual y que ha permitido que tanto los alumnos como al docente tratar de eliminar algunas desventajas de la enseñanza tradicional. Ya que se observaron cambios significativos e importantes, lo que quedó de manifiesto en las calificaciones promedio de los grupos obtenidas en la Unidad de aprendizaje Bioquímica en la especialidad en Función Visual. Los resultados obtenidos además de las habilidades y competencias que adquirieron los estudiantes fueron sumamente satisfactorios para los estudiantes y docentes participantes.The National Polytechnic Institute is in a period of change, which has led to the creation of new educational proposals aimed at promoting learning including virtual education, which in recent years has favored the emergence and consolidation of Degrees, Diplomas, Specialties, Masters including using distance learning based on a web environment. This work collects the experience you have had in the Biochemistry course taught in the specialty of visual function and that have allowed both students and teachers try to eliminate some disadvantages of traditional teaching. As significant and important changes were observed, which was evident in the average scores of the groups obtained in the Unit of Biochemistry specialty learning in visual function? The results along with the skills and competencies that students acquired obtained were highly satisfactory for students and teachers participating

    A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Get PDF
    Introduction: A recent genome-wide association study (GWAS) comprising a French cohort of systemic sclerosis (SSc) reported several non-HLA single-nucleotide polymorphisms (SNPs) showing a nominal association in the discovery phase. We aimed to identify previously overlooked susceptibility variants by using a follow-up strategy.<p></p> Methods: Sixty-six non-HLA SNPs showing a P value <10-4 in the discovery phase of the French SSc GWAS were analyzed in the first step of this study, performing a meta-analysis that combined data from the two published SSc GWASs. A total of 2,921 SSc patients and 6,963 healthy controls were included in this first phase. Two SNPs, PPARG rs310746 and CHRNA9 rs6832151, were selected for genotyping in the replication cohort (1,068 SSc patients and 6,762 healthy controls) based on the results of the first step. Genotyping was performed by using TaqMan SNP genotyping assays. Results: We observed nominal associations for both PPARG rs310746 (PMH = 1.90 × 10-6, OR, 1.28) and CHRNA9 rs6832151 (PMH = 4.30 × 10-6, OR, 1.17) genetic variants with SSc in the first step of our study. In the replication phase, we observed a trend of association for PPARG rs310746 (P value = 0.066; OR, 1.17). The combined overall Mantel-Haenszel meta-analysis of all the cohorts included in the present study revealed that PPARG rs310746 remained associated with SSc with a nominal non-genome-wide significant P value (PMH = 5.00 × 10-7; OR, 1.25). No evidence of association was observed for CHRNA9 rs6832151 either in the replication phase or in the overall pooled analysis.<p></p> Conclusion: Our results suggest a role of PPARG gene in the development of SSc

    Cross-disease Meta-analysis of Genome-wide Association Studies for Systemic Sclerosis and Rheumatoid Arthritis Reveals IRF4 as a New Common Susceptibility Locus

    Get PDF
    Objectives: Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are autoimmune diseases that share clinical and immunological characteristics. To date, several shared SSc- RA loci have been identified independently. In this study, we aimed to systematically search for new common SSc-RA loci through an inter-disease meta-GWAS strategy. Methods: We performed a meta-analysis combining GWAS datasets of SSc and RA using a strategy that allowed identification of loci with both same-direction and opposingdirection allelic effects. The top single-nucleotide polymorphisms (SNPs) were followed-up in independent SSc and RA case-control cohorts. This allowed us to increase the sample size to a total of 8,830 SSc patients, 16,870 RA patients and 43,393 controls. Results: The cross-disease meta-analysis of the GWAS datasets identified several loci with nominal association signals (P-value < 5 x 10-6), which also showed evidence of association in the disease-specific GWAS scan. These loci included several genomic regions not previously reported as shared loci, besides risk factors associated with both diseases in previous studies. The follow-up of the putatively new SSc-RA loci identified IRF4 as a shared risk factor for these two diseases (Pcombined = 3.29 x 10-12). In addition, the analysis of the biological relevance of the known SSc-RA shared loci pointed to the type I interferon and the interleukin 12 signaling pathways as the main common etiopathogenic factors. Conclusions: Our study has identified a novel shared locus, IRF4, for SSc and RA and highlighted the usefulness of cross-disease GWAS meta-analysis in the identification of common risk loci

    Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA)

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>The EURIKA study aims to assess the status of primary prevention of cardiovascular disease (CVD) across Europe. Specifically, it will determine the degree of control of cardiovascular risk factors in current clinical practice in relation to the European guidelines on cardiovascular prevention. It will also assess physicians' knowledge and attitudes about CVD prevention as well as the barriers impeding effective risk factor management in clinical practice.</p> <p>Methods/Design</p> <p>Cross-sectional study conducted simultaneously in 12 countries across Europe. The study has two components: firstly at the physician level, assessing eight hundred and nine primary care and specialist physicians with a daily practice in CVD prevention. A physician specific questionnaire captures information regarding physician demographics, practice settings, cardiovascular prevention beliefs and management. Secondly at the patient level, including 7641 patients aged 50 years or older, free of clinical CVD and with at least one classical risk factor, enrolled by the participating physicians. A patient-specific questionnaire captures information from clinical records and patient interview regarding sociodemographic data, CVD risk factors, and current medications. Finally, each patient provides a fasting blood sample, which is sent to a central laboratory for measuring serum lipids, apolipoproteins, hemoglobin-A1c, and inflammatory biomarkers.</p> <p>Discussion</p> <p>Primary prevention of CVD is an extremely important clinical issue, with preventable circulatory diseases remaining the leading cause of major disease burden. The EURIKA study will provide key information to assess effectiveness of and attitudes toward primary prevention of CVD in Europe. A transnational study creates opportunities for benchmarking good clinical practice across countries and improving outcomes. (ClinicalTrials.gov number, NCT00882336.)</p

    Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Get PDF
    Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio
    corecore